Investor Call - Q List

A place to collate questions for the investor call. If / when they are answered I'll create a new thread with the questions asked and answers provided. Mine are below, won't be able to dial in (work) so if anyone can ask them, would be appreciated. I will listen to the recording afterward and note down answers to any questions.


Questions:
Is this a failure of the underlying technology and machine learning algorithm or is it purely a failure of the way the trial was conducted? What percentage of the failure of the study can be ascribed to the failure to adhere to protocols?

How can you substantiate the answer the above?

How can you explain the large statistical disparity beteeen the Australian and US results (in scientific, not narrative terms)?

Can you specifically identify the deficiencies in the samples that WERE analysed that could have contributed to the results?

Is there a way to ensure the trial protocol is strictly adhered to while maintaining the double blind trial integrity (pretty sure there is)